Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
351 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atopic Dermatitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Atopic dermatitis - Pipeline Review, H1 2016', provides an overview of the Atopic dermatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atopic dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic dermatitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Atopic dermatitis - The report reviews pipeline therapeutics for Atopic dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Atopic dermatitis therapeutics and enlists all their major and minor projects - The report assesses Atopic dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Atopic dermatitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Atopic dermatitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Atopic dermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Atopic Dermatitis Overview 11 Therapeutics Development 12 Pipeline Products for Atopic Dermatitis - Overview 12 Pipeline Products for Atopic Dermatitis - Comparative Analysis 13 Atopic Dermatitis - Therapeutics under Development by Companies 14 Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20 Atopic Dermatitis - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Atopic Dermatitis - Products under Development by Companies 25 Atopic Dermatitis - Products under Investigation by Universities/Institutes 32 Atopic Dermatitis - Companies Involved in Therapeutics Development 33 Abeome Corporation 33 Accolade Pharmaceuticals, LLC 34 AlbireoPharma 35 Almirall, S.A. 36 Amgen Inc. 37 Amorepacific Corporation 38 Anacor Pharmaceuticals, Inc. 39 AnaMar AB 40 AnaptysBio, Inc. 41 AnGes MG, Inc. 42 Aquinox Pharmaceuticals Inc. 43 arGEN-X BV 44 Blueberry Therapeutics Ltd 45 Brickell Biotech, Inc. 46 Celgene Corporation 47 ChemoCentryx, Inc. 48 ChironWells GmbH 49 Chugai Pharmaceutical Co., Ltd. 50 Creabilis SA 51 Delenex Therapeutics AG 52 Dermira Inc. 53 Dr. August Wolff GmbH & Co. KG Arzneimittle 54 Eli Lilly and Company 55 F. Hoffmann-La Roche Ltd. 56 Foamix Pharmaceuticals Ltd. 57 Fountain Biopharma Inc. 58 GlaxoSmithKline Plc 59 Glenmark Pharmaceuticals Ltd. 60 Grupo Ferrer Internacional, S.A. 61 Han Wha Pharma Co., Ltd. 62 HanAll Biopharma Co., Ltd. 63 Herantis Pharma Plc 64 Immune Pharmaceuticals Inc. 65 Inflamalps SA 66 Japan Tobacco Inc. 67 Johnson & Johnson 68 Kineta, Inc. 69 LegoChem Biosciences, Inc 70 LEO Pharma A/S 71 Madam Therapeutics B.V. 72 MedImmune, LLC 73 NeoPharm Co., Ltd. 74 Novan, Inc. 75 Novartis AG 76 Orbis Biosciences, Inc. 77 Otsuka Holdings Co., Ltd. 78 Oxagen Limited 79 Pfizer Inc. 80 Pharis Biotec GmbH 81 Pharmedartis GmbH 82 Provectus Biopharmaceuticals, Inc. 83 Regeneron Pharmaceuticals, Inc. 84 Signum Dermalogix, Inc 85 Spherium Biomed S.L. 86 sterna biologicals Gmbh & Co KG 87 Sucampo Pharmaceuticals, Inc. 88 Sun Pharma Advanced Research Company Ltd. 89 SWITCH Biotech LLC 90 Takeda Pharmaceutical Company Limited 91 Thesan Pharmaceuticals, Inc. 92 Valeant Pharmaceuticals International, Inc. 93 Vicore Pharma AB 94 Vitae Pharmaceuticals, Inc. 95 VivaCell Biotechnology Espana S.L. 96 Xencor, Inc. 97 Ziarco Pharma Ltd 98 Atopic Dermatitis - Therapeutics Assessment 99 Assessment by Monotherapy Products 99 Assessment by Target 100 Assessment by Mechanism of Action 105 Assessment by Route of Administration 109 Assessment by Molecule Type 111 Drug Profiles 113 A-3914 - Drug Profile 113 A-5425 - Drug Profile 114 AKP-11 - Drug Profile 115 ALX-101 - Drug Profile 117 AM-1030 - Drug Profile 118 AN-4161 - Drug Profile 119 ANB-020 - Drug Profile 120 apremilast - Drug Profile 121 Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 124 AQX-1125 - Drug Profile 125 ARGX-112 - Drug Profile 128 ARN-077 - Drug Profile 129 baricitinib - Drug Profile 130 BB-2702 - Drug Profile 133 BBI-2000 - Drug Profile 134 BBI-5000 - Drug Profile 135 bertilimumab - Drug Profile 136 Biologic for Atopic Dermatitis and Eczema - Drug Profile 138 C-21 - Drug Profile 139 CBP-174 - Drug Profile 141 CBP-201 - Drug Profile 142 CCX-6239 - Drug Profile 143 CDE-001 - Drug Profile 144 Cis-Urocanic Acid - Drug Profile 145 CNTO-7160 - Drug Profile 148 cobamamide - Drug Profile 149 crisaborole - Drug Profile 150 CT-101 - Drug Profile 152 CT-1x1 - Drug Profile 153 CT-1x2 - Drug Profile 154 CT-1x3 - Drug Profile 155 CT-327 - Drug Profile 156 CT-340 - Drug Profile 158 cyclosporine - Drug Profile 159 dalazatide - Drug Profile 160 DMT-210 - Drug Profile 162 DRM-02 - Drug Profile 163 Drug for Atopic Dermatitis - Drug Profile 164 Drugs to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 165 dupilumab - Drug Profile 166 FB-825 - Drug Profile 169 fevipiprant - Drug Profile 170 FIB-116 - Drug Profile 172 Furestem-AD - Drug Profile 173 GBR-830 - Drug Profile 174 Histimex - Drug Profile 175 HS-378 - Drug Profile 176 JTE-052 - Drug Profile 177 KPI-150 - Drug Profile 178 LCB-030110 - Drug Profile 179 lebrikizumab - Drug Profile 180 LEKTI-6 - Drug Profile 182 LEO-32731 - Drug Profile 183 LEO-39652 - Drug Profile 184 mepolizumab - Drug Profile 185 MLR-1130 - Drug Profile 188 mometasone furoate - Drug Profile 189 Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile 190 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 191 Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile 192 N-oleoylethanolamine - Drug Profile 193 nemolizumab - Drug Profile 194 NPH-12 - Drug Profile 195 OC-000459 - Drug Profile 196 OC-2417 - Drug Profile 198 octenidine hydrochloride - Drug Profile 199 OLX-103 - Drug Profile 200 omiganan pentahydrochloride - Drug Profile 201 OPA-15406 - Drug Profile 203 P-10 - Drug Profile 204 PAC-14028 - Drug Profile 205 PDI-192 - Drug Profile 207 Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 208 Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 209 PH-10 - Drug Profile 210 PL-601 - Drug Profile 212 PMA-101R - Drug Profile 213 PMA-201 - Drug Profile 214 PMA-411R - Drug Profile 215 prednisone - Drug Profile 216 PZ-235 - Drug Profile 217 Q-301 - Drug Profile 218 Qi-507 - Drug Profile 219 roflumilast - Drug Profile 220 RTU-1096 - Drug Profile 223 RVT-501 - Drug Profile 224 S-414114 - Drug Profile 225 SB-011 - Drug Profile 227 SB-414 - Drug Profile 228 SIG-1311 - Drug Profile 229 SIG-1322 - Drug Profile 231 Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 232 Small Molecules for Atopic Dermatitis - Drug Profile 233 SP-14019 - Drug Profile 234 SUN-0597 - Drug Profile 235 SWT-01113 - Drug Profile 237 SWT-05141 - Drug Profile 238 Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 239 tacrolimus - Drug Profile 240 tezepelumab - Drug Profile 241 tofacitinib - Drug Profile 243 tralokinumab - Drug Profile 247 ustekinumab - Drug Profile 249 VTP-38543 - Drug Profile 252 WBI-1001 - Drug Profile 253 WOL-071007 - Drug Profile 255 XmAb-7195 - Drug Profile 256 YJC-10592 - Drug Profile 257 Zafi-1 - Drug Profile 258 ZPL-3893787 - Drug Profile 259 ZPL-5212372 - Drug Profile 260 Atopic Dermatitis - Recent Pipeline Updates 261 Atopic Dermatitis - Dormant Projects 324 Atopic Dermatitis - Discontinued Products 334 Atopic Dermatitis - Product Development Milestones 336 Featured News & Press Releases 336 Appendix 342 Methodology 342 Coverage 342 Secondary Research 342 Primary Research 342 Expert Panel Validation 342 Contact Us 342 Disclaimer 343
List of Tables Number of Products under Development for Atopic Dermatitis, H1 2016 20 Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H1 2016 21 Number of Products under Development by Companies, H1 2016 22 Number of Products under Development by Companies, H1 2016 (Contd..1) 23 Number of Products under Development by Companies, H1 2016 (Contd..2) 24 Number of Products under Development by Companies, H1 2016 (Contd..3) 25 Number of Products under Development by Companies, H1 2016 (Contd..4) 26 Number of Products under Development by Companies, H1 2016 (Contd..5) 27 Number of Products under Investigation by Universities/Institutes, H1 2016 28 Comparative Analysis by Late Stage Development, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Development, H1 2016 31 Comparative Analysis by Unknown Stage Development, H1 2016 32 Products under Development by Companies, H1 2016 33 Products under Development by Companies, H1 2016 (Contd..1) 34 Products under Development by Companies, H1 2016 (Contd..2) 35 Products under Development by Companies, H1 2016 (Contd..3) 36 Products under Development by Companies, H1 2016 (Contd..4) 37 Products under Development by Companies, H1 2016 (Contd..5) 38 Products under Development by Companies, H1 2016 (Contd..6) 39 Products under Investigation by Universities/Institutes, H1 2016 40 Atopic Dermatitis - Pipeline by Abeome Corporation, H1 2016 41 Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016 42 Atopic Dermatitis - Pipeline by AlbireoPharma, H1 2016 43 Atopic Dermatitis - Pipeline by Almirall, S.A., H1 2016 44 Atopic Dermatitis - Pipeline by Amgen Inc., H1 2016 45 Atopic Dermatitis - Pipeline by Amorepacific Corporation, H1 2016 46 Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 47 Atopic Dermatitis - Pipeline by AnaMar AB, H1 2016 48 Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H1 2016 49 Atopic Dermatitis - Pipeline by AnGes MG, Inc., H1 2016 50 Atopic Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 51 Atopic Dermatitis - Pipeline by arGEN-X BV, H1 2016 52 Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2016 53 Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2016 54 Atopic Dermatitis - Pipeline by Celgene Corporation, H1 2016 55 Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H1 2016 56 Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2016 57 Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 58 Atopic Dermatitis - Pipeline by Creabilis SA, H1 2016 59 Atopic Dermatitis - Pipeline by Delenex Therapeutics AG, H1 2016 60 Atopic Dermatitis - Pipeline by Dermira Inc., H1 2016 61 Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 62 Atopic Dermatitis - Pipeline by Eli Lilly and Company, H1 2016 63 Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 64 Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 65 Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H1 2016 66 Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2016 67 Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 68 Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 69 Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H1 2016 70 Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 71 Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H1 2016 72 Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H1 2016 73 Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2016 74 Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H1 2016 75 Atopic Dermatitis - Pipeline by Johnson & Johnson, H1 2016 76 Atopic Dermatitis - Pipeline by Kineta, Inc., H1 2016 77 Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2016 78 Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2016 79 Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H1 2016 80 Atopic Dermatitis - Pipeline by MedImmune, LLC, H1 2016 81 Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H1 2016 82 Atopic Dermatitis - Pipeline by Novan, Inc., H1 2016 83 Atopic Dermatitis - Pipeline by Novartis AG, H1 2016 84 Atopic Dermatitis - Pipeline by Orbis Biosciences, Inc., H1 2016 85 Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 86 Atopic Dermatitis - Pipeline by Oxagen Limited, H1 2016 87 Atopic Dermatitis - Pipeline by Pfizer Inc., H1 2016 88 Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2016 89 Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2016 90 Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 91 Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 92 Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H1 2016 93 Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H1 2016 94 Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 95 Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 96 Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 97 Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2016 98 Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 99 Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016 100 Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 101 Atopic Dermatitis - Pipeline by Vicore Pharma AB, H1 2016 102 Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 103 Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 104 Atopic Dermatitis - Pipeline by Xencor, Inc., H1 2016 105 Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H1 2016 106 Assessment by Monotherapy Products, H1 2016 107 Number of Products by Stage and Target, H1 2016 109 Number of Products by Stage and Mechanism of Action, H1 2016 114 Number of Products by Stage and Route of Administration, H1 2016 118 Number of Products by Stage and Molecule Type, H1 2016 120 Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H1 2016 269 Atopic Dermatitis - Dormant Projects, H1 2016 332 Atopic Dermatitis - Dormant Projects (Contd..1), H1 2016 333 Atopic Dermatitis - Dormant Projects (Contd..2), H1 2016 334 Atopic Dermatitis - Dormant Projects (Contd..3), H1 2016 335 Atopic Dermatitis - Dormant Projects (Contd..4), H1 2016 336 Atopic Dermatitis - Dormant Projects (Contd..5), H1 2016 337 Atopic Dermatitis - Dormant Projects (Contd..6), H1 2016 338 Atopic Dermatitis - Dormant Projects (Contd..7), H1 2016 339 Atopic Dermatitis - Dormant Projects (Contd..8), H1 2016 340 Atopic Dermatitis - Dormant Projects (Contd..9), H1 2016 341 Atopic Dermatitis - Discontinued Products, H1 2016 342 Atopic Dermatitis - Discontinued Products (Contd..1), H1 2016 343
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
